JNJ Edges Out Coca-Cola in Defensive Rally on Pipeline Strength
Capital rotating out of tech is lifting both Johnson & Johnson and Coca-Cola, but JNJ's pharmaceutical pipeline offers a more sustainable growth driver than KO's reliance on pricing.
Johnson & Johnson and Coca-Cola both hit new highs this week after posting first-quarter 2026 earnings beats, capturing capital fleeing the technology sector. JNJ broke past $259, while KO tagged an all-time high near $84.14. However, a closer look at the underlying fundamentals reveals a clear winner for investors seeking a defensive anchor.
JNJ reported $24.062 billion in revenue, up 9.9% year over year, with adjusted earnings per share of $2.70. The strength lies in its pharmaceutical portfolio, where DARZALEX generated $3.964 billion and TREMFYA surged 68.3% to $1.608 billion. These two drugs are successfully absorbing the 59.7% revenue collapse of STELARA due to biosimilar competition. CEO Joaquin Duato called it "a strong start to 2026" and raised full-year revenue guidance to a range of $100.3 billion to $101.3 billion.
Coca-Cola delivered a cleaner top-line number, with revenue rising 12.1% to $12.472 billion and EPS of $0.86 beating estimates by 5.87%. New CEO Henrique Braun credited "staying close to the consumer, executing locally and managing complexity" as operating margins widened to 35.0% from 32.9%. Zero Sugar volumes climbed 13% globally, yet total organic volume grew just 3%. This indicates that nearly all of Coca-Cola's revenue growth came from price increases rather than actual unit demand.
That dynamic makes JNJ the superior risk-reward play at current multiples. JNJ trades at a 23 times forward price-to-earnings ratio, a discount to KO's 26 times multiple, despite JNJ delivering double-digit oncology and immunology growth. Polymarket traders evidently agree, pricing a 92% probability that JNJ beats its next earnings report.
JNJ's headline figures are weighed down by a 52.4% drop in net income due to $330 million in litigation charges and declining free cash flow. Yet, the company holds 28 separate billion-dollar platforms and is planning an Orthopaedics spin-off to unlock value. By contrast, KO's pristine margins mask a fragile reality: pricing-driven growth works until consumer wallets tighten and volume stalls. For portfolio managers building a defensive moat, pharma innovation currently offers a better hedge than beverage pricing power.
